The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
In ANY AIM Co it is potential vs reality. That is until potential matches reality too break even, profitability, or not. What you are saying is that this principle is floored. My question is why are you bothered.
TGTD, I will put forward the following facts:
DDR assay developed for Artois for which Angle were paid and now Angle are actively marketing to other customers!
Her2 assay developed for Eisai (Japan) for which Angle will be paid £250k - this is a favourite of derampers 🤡. Who knows, it could lead to a bigger contract?
All I would say is Angle are picking the low hanging fruit and thank goodness they are and not reaching for all cancer validation. That would be nuts 🐿️
Re NGS. Dunno. They have said they have work to do on this and that is the way I read things first time reading the RNS. I was actually surprised that news did so well but it took me a little time to fully appreciate. I am sure you will feel the same way too at some point.
ATB
Really? 24 cancer types? One step at a time...The FDA already told Angle to rethink a whole cancer approach and address each cancer type one at a time. Would cost billions to tackle all cancers!
TGTD,
You talk about financial realities but with a long term view. You do not however acknowledge the potential and May I remind you that this share hit 37p a couple of weeks ago based on potential. Imo your posts lack balance and you in fact require others to make the balance for you. When people do you argue and talk down to people. So basically people ignore you I guess?
What I am wondering is besides the two NGS systems (illumina and Thermo Fisher which have been named dropped recently by AN and IG) are there any other NGS systems that Angle could use or are there any other none NGS platforms that could be used and which would offer particular benefits and limitations. So essentially, what is the thinking that Angle has had to undertake to present the best results. Sorry if that is a massive question. It may well just be one of the lead NGS systems which would be fine wouldn't it.
Mia,
You are right to underline Angles strategy of utilising the installed base of some 3000+ NGS systems. If Parsortix is a seamless fit why not! Also the economy point you make re: Ziplex is spot on thanks.
I also wonder what the benefits or limitations might be of choosing NGS to process these samples. It is clear that after using its own in house molecular system that Angle have to get this right so that the results are beyond dispute
From today's RNS:
Harvested CTCs also have the added advantage in that they can undergo RNA, protein, and morphological analysis, thus combining genotype with phenotype to give a comprehensive biomarker profile. These recent advances in molecular oncology, combined with broad phenotyping including protein expression and analysis of methylation patterns are driving the implementation of precision oncology, with the aim of improving patient care.
AN mentioned in the recent proactive one2one that Angle were looking at the stored samples for prostate and ovarian being tested by third party systems. He mentioned NGS in the same breath so I am wondering if either Illumina or Thermo Fisher will be chosen as the third party platform as both dominate NGS and can be used for molecular analysis. Presumably there would be a cost attached to using either system if Angle do not have them readily installed?
Following on re AvidiMab. If I company were taking a look at it re: suitability at what stage of work would we expect an RNS? Is it possible that some preclinical testing would not require disclosure to the market?
TGTD
To clarify your point; which I take to indicate an excellent route to market…
An accredited lab can use a Parsortix device using a test that they develop and validate. So Angle sell a device and most likely more than one so that the amount of tests carried out are meaningful £🤩$👍€. And they would of course need consumables at £300 a pop.
Oh you tamper you 😅
Well Angle could be accused of diving into many a rabbit hole but this one could lead to wonderland?!
Thanks Thompi for the link. Personally I think it is right on the money and seems to be where Angle are headed.
Look at OBD, POLX, RENE, ANGLE. All need to commercialise! They all have outstanding tests/device but they have to match these to the needs of customers, end users, and patients. No point having a test if it is not useable! So I am afraid that anybody complaining that FDA did not equal instant sales was either unaware of the reality of getting product's, test or devices to market. The common denominator is lack of awareness, knowledge and experience and I am afraid that is the responsibility solely of the investor. So there really is no point blaming the companies...
Truth hurts I am afraid but many will learn for next time.
I would say why quit now when the hard work is pretty much done?
The FDA was indeed a highlight, however looking at the Proactive One2One presentation things have moved on to bring the Parsortix device closer to the end user. We all have an opinion on how close that is, and knowing SK as we do I'd say he would be objective in his analysis as always. I am pretty sure he recognises what has appeared to be a baron period for Angle over the last 18 months was in fact a preparatory period in which the seeds have been sown. Now all we need to do is reap the harvest.
Thinking about a point I made earlier. Checkpoint inhibitors are not suitable or effective for all patients. But, if iSCIB1+ does what is expected then a whole lot more people (than SCIB1 40%) will get the benefit. Now just for perspective this am I have watched a presentation by a CTC capture company and read an RNS on a checkpoint inhibitor test company who would argue that 1. each patients cancer is different 2. each patient is different and 3. each patients tolerance to different drugs is different. In fact these critical questions apply across the board. Fascinating then to see how the SCOPE trial fairs with these three question! In its SCIB1 guise it was indeed, encouraging, promising and exceptional it appears ratcliifewriter. Hopeful for iSCIB1+ but we cannot really hope for 85% ORR can we? Although I have everything crossed!